Last reviewed · How we verify
Statins with or without ezetimibe
Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, while ezetimibe inhibits the absorption of cholesterol in the small intestine.
Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, while ezetimibe inhibits the absorption of cholesterol in the small intestine. Used for Hyperlipidemia, Atherosclerotic cardiovascular disease.
At a glance
| Generic name | Statins with or without ezetimibe |
|---|---|
| Also known as | Hydroxymethylglutaryl-Coenzyme A Reductase inhibitors, Ezetimibe |
| Sponsor | Beijing Anzhen Hospital |
| Drug class | HMG-CoA reductase inhibitor |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Statins work by reducing the amount of cholesterol produced in the liver, which in turn lowers the amount of low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe, on the other hand, blocks the absorption of cholesterol in the small intestine, further reducing the amount of cholesterol available to the body.
Approved indications
- Hyperlipidemia
- Atherosclerotic cardiovascular disease
Common side effects
- Muscle pain
- Liver enzyme elevation
- Diarrhea
Key clinical trials
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (PHASE3)
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2) (NA)
- Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study (PHASE4)
- RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy (NA)
- Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
- Genetic Testing and Motivational Counseling for FH (NA)
- Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis (PHASE3)
- In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Statins with or without ezetimibe CI brief — competitive landscape report
- Statins with or without ezetimibe updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI